

Agendia Breast Cancer Test Suite



The biology of your breast cancer is unique. Identifying the most effective, tailored therapies for your tumor is called *Personalized Medicine*, which starts with *Precision Science* -- which is what we do at Agendia. Traditionally, physicians have relied on clinical-pathological factors such as age, tumor size, tumor grade, lymph node involvement, and hormone receptor status to make breast cancer treatment decisions. While this information is useful, The Agendia Breast Cancer Test Suite uncovers your hidden breast cancer biology, providing you and your physician more information to help determine the most appropriate treatments for your specific tumor. Please see the descriptions below to learn more about the Agendia Breast Cancer Test Suite.

Test Name

Test Description



mammaprint[®]

70-Gene Breast Cancer Recurrence Assay

70-Gene Breast Cancer Recurrence Assay: MammaPrint[®] is the only breast cancer recurrence assay backed peer-reviewed, prospective outcome data. Unlike other tests, you are given definitive Low Risk and High Risk results, eliminating the uncertainty of an intermediate risk score which can affect up to 39% of patients tested¹. A Low Risk result means you have a 10%, or 1 in 10 chance of your cancer returning. A High Risk result means you have a 29%, or 3 out of 10 chance of it returning. These results are based on a 10-year follow-up of a reference group of patients who had no additional treatment². A Low Risk result doesn't guarantee that your cancer will not recur, and a High Risk result doesn't guarantee that your cancer will. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.



blueprint[®]

80-Gene Molecular Subtyping Assay

80-Gene Molecular Subtyping Assay: Blueprint[®] molecular subtyping provides deeper insight into tumor pathways, uncovering your hidden tumor biology. Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are really driving the tumor's behavior. Combined with MammaPrint, Blueprint will uncover if your breast cancer is Luminal-type (A or B), Basal-type, or HER2-type. These findings are important when determining the treatments that are most appropriate for your specific tumor.



targetprint[®]

ER/PR/HER2 Gene Expression Assay

ER/PR/HER2 Expression Assay: TargetPrint[®] determines the receptor status of your tumor using gene-expression technology. Un-biased, quantitative assessment of ER, PR & HER2 expression adds confidence to your conventional hormone receptor status results. Studies have shown that IHC misclassification can occur in up to 30% of cases³. Accurate assessment of hormone receptor status is important since these biomarkers have shown to be predictive of therapeutic response such as endocrine therapy (Tamoxifen[®]) for ER+ patients and trastuzumab (Herceptin[®]) for HER2+ patients.

Learn more about breast cancer treatment by visiting www.knowyourbreastcancer.com or connect with a support group through the *Symphony Sisterhood* on Facebook



References:

1. Carlson JJ, et al. *Breast Cancer Res Treat.* 2013 Aug;141(1): 13–22.
2. Buyse M, Loi S, van 't Veer LJ, et. al., *J Natl Cancer Inst* 2006; 98(17):1183-1192.
3. Allred DC. *The Oncologist.* Nov 2008; vol. 13 no. 11:1134-1136.

22 Morgan | Irvine | CA 92618 | p: 888.321.2732 | f: 888.756.7548
customer@agendia.com | www.agendia.com

Patient information about insurance coverage and assistance from Agendia

Our mission is to ensure all breast cancer patients have access to important, and clinically relevant molecular diagnostic testing empowering patients and physicians to make the most informed treatment decisions. Agendia understands that costs associated with a patient's diagnosis, treatment, and management of breast cancer can potentially pose a financial hardship which may influence a patient's decision in selecting diagnostic and treatment options. The following information will inform you about financial responsibility associated with performing any of Agendia's tests.

Q: How much will I personally have to pay for my test(s)?

A: Many insurance carriers cover most types of genomic testing for breast cancer. Like each patient, every case is unique, and the average out-of-pocket amount varies based on: insurance benefits, what portion of your deductible has been met and your co-pay amounts. If you have active insurance coverage at the time of testing, Agendia can provide you with an estimate of your financial responsibility based on your specific benefit levels. Please call 888.363.7868 and one of our Patient Advocate Representatives will gladly assist you.

Q: What are my payment options if I have a balance due?

A: If payment is required after your insurance company has determined their coverage, Agendia will work on your behalf to ensure that the insurance company has processed the claim at the highest benefit level to minimize any out-of-pocket expense. After a full review, an invoice will be issued for any difference in coverage. If you are interested in arranging an interest-free payment plan, please contact us and one of our Patient Advocates can assist you with this.

Q: What if I get a bill from Agendia for more than I expected?

A: Please contact us and one of our Patient Advocates will work to resolve the discrepancy in an acceptable and timely manner. They can be reached at 888.363.7868.

Q: My insurance company sent me something that looks like a bill for this test. Should I pay it?

A: Your insurance company may send you one or more Explanation of Benefits (EOB) statements related to our test(s). This is not a bill from Agendia. Agendia can submit an appeal(s) on your behalf during the claim review process and each appeal submitted will generate an EOB from your insurance company. You do not have any financial obligation for the test, unless you receive an invoice from Agendia.

Agendia is a compassionate company offering a wide range of financial assistance programs based on individual financial status. Agendia offers the following programs to meet your financial needs:

- Interest-free payment plans
- Uninsured patient assistance
- Underinsured patient assistance
- Indigent patient assistance

For more information, or to speak with a Patient Advocate Representative, call us at **888.363.7868** or email at billing@agendia.com